Cefazolin Dosing for Tracheitis
For tracheitis treatment, cefazolin should be administered at a dose of 100 mg/kg/day IV divided every 8 hours up to a maximum of 12 g daily. 1
Dosing Considerations
Adult Dosing
- Standard adult dose: 1-2 g IV every 8 hours 2
- For severe infections: Consider 2 g IV every 8 hours
- Maximum daily dose: 12 g daily 1
Pediatric Dosing
Renal Adjustment
- For patients with renal impairment, dose adjustment is essential to prevent neurotoxicity 3:
- CrCl 35-54 mL/min: Full dose every 8-12 hours
- CrCl 11-34 mL/min: Full dose every 12 hours
- CrCl ≤10 mL/min: Full dose every 24 hours
Treatment Duration
- For uncomplicated tracheitis: 5-7 days
- For severe infections: 7-14 days
- Continue treatment until clinical improvement is observed and for at least 48-72 hours after fever resolution
Monitoring Parameters
- Clinical response within 72 hours
- Signs of neurotoxicity, especially in patients with renal impairment 3
- Complete blood count and renal function tests periodically
Alternative Agents
If cefazolin is not appropriate (e.g., allergy, resistance):
For beta-lactam allergic patients:
For suspected MRSA:
Pharmacokinetic Considerations
- Cefazolin demonstrates excellent tissue penetration with a tissue/serum ratio of approximately 1.06 4
- Peak serum concentrations after standard dosing are typically 25-216 μg/mL, which exceeds the MIC for most susceptible pathogens 5, 6
- The drug has a half-life of 1.5-2.5 hours in patients with normal renal function 7
Practical Administration Tips
- Administer IV doses slowly over 30 minutes to reduce the risk of adverse reactions
- For IV administration, reconstitute with appropriate diluent per institutional protocols
- Monitor injection sites for signs of phlebitis or inflammation
Cautions
- Risk of seizures with excessive dosing, particularly in patients with renal impairment 3
- Potential for cross-reactivity in patients with penicillin allergy (approximately 10%)
- Monitor for superinfection, especially with prolonged use
Cefazolin is an effective first-generation cephalosporin with excellent activity against many pathogens commonly associated with tracheitis, including methicillin-susceptible Staphylococcus aureus and streptococci 6, 7.